Rafal Dziadziuszko1, Egbert F Smit2, Urania Dafni3, Juergen Wolf4, Bartosz Wasąg5, Wojciech Biernat6, Stephen P Finn7, Roswitha Kammler8, Zoi Tsourti9, Manuela Rabaglio8, Barbara Ruepp8, Heidi Roschitzki-Voser8, Rolf A Stahel10, Enriqueta Felip11, Solange Peters12. 1. Medical University of Gdansk, Department of Oncology and Radiotherapy, Gdansk, Poland. 2. VU University Medical Center, Department of Pulmonary Diseases & Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands. 3. Frontier Science Foundation-Hellas & National and Kapodistrian University of Athens, Athens, Greece. 4. University Hospital Cologne, Department of Internal Medicine, Cologne, Germany. 5. Medical University of Gdansk, Department of Biology and Genetics, Gdansk, Poland. 6. Medical University of Gdansk, Department of Pathology, Gdansk, Poland. 7. Cancer Molecular Diagnostics, St. James's Hospital and Trinity College, Dublin, Ireland. 8. European Thoracic Oncology Platform (ETOP), Bern, Switzerland. 9. Frontier Science Foundation-Hellas, Athens, Greece. 10. University Hospital Zurich, Clinic of Oncology, Zurich, Switzerland. 11. Vall d'Hebron University Hospital, Institute of Oncology, Barcelona, Spain. 12. Centre Hospitalier Universitaire Vaudois (CHUV), Département d'Oncologie, Lausanne, Switzerland. Electronic address: Solange.Peters@chuv.ch.
Abstract
INTRODUCTION: Mutations in erb-b2 receptor tyrosine kinase 2 (HER2) oncogene are observed in approximately 3% of lung adenocarcinomas or mixed tumors with adenocarcinoma component. Activity of various biologically distinct HER2 inhibitors, including the pan-HER inhibitor afatinib, has been reported in several retrospective trials or small series in advanced pretreated NSCLC with HER2 mutations. We report the first prospective evaluation of afatinib for the treatment of this molecularly defined entity. METHODS: NICHE, a single-arm phase II trial using a two-stage Simon's design, explored the potential of afatinib to control disease in pretreated patients with advanced NSCLC harboring HER2 exon 20 mutations. A total of 13 patients entered the trial and were treated with afatinib 40 mg/day until tumor progression or lack of tolerability. RESULTS: The first-stage stopping boundary was crossed when five of nine patients did not achieve disease control at 12 weeks. The accrual into the trial was stopped with total 13 patients enrolled, with 7 (53.8%) achieving disease control at 12 weeks. Except for 1 patient with early death, progression was documented for all patients, with median progression-free survival of 15.9 weeks (95% confidence interval: 6.0-35.4), and median overall survival of 56.0 weeks (95% confidence interval: 16.3- upper limit not estimable). The toxicity profile was in the expected range. CONCLUSIONS: Afatinib did not show the expected potential for disease control in NSCLC. However, more than half of the patients in the full cohort achieved disease control at 12 weeks.
INTRODUCTION: Mutations in erb-b2 receptor tyrosine kinase 2 (HER2) oncogene are observed in approximately 3% of lung adenocarcinomas or mixed tumors with adenocarcinoma component. Activity of various biologically distinct HER2 inhibitors, including the pan-HER inhibitor afatinib, has been reported in several retrospective trials or small series in advanced pretreated NSCLC with HER2 mutations. We report the first prospective evaluation of afatinib for the treatment of this molecularly defined entity. METHODS: NICHE, a single-arm phase II trial using a two-stage Simon's design, explored the potential of afatinib to control disease in pretreated patients with advanced NSCLC harboring HER2 exon 20 mutations. A total of 13 patients entered the trial and were treated with afatinib 40 mg/day until tumor progression or lack of tolerability. RESULTS: The first-stage stopping boundary was crossed when five of nine patients did not achieve disease control at 12 weeks. The accrual into the trial was stopped with total 13 patients enrolled, with 7 (53.8%) achieving disease control at 12 weeks. Except for 1 patient with early death, progression was documented for all patients, with median progression-free survival of 15.9 weeks (95% confidence interval: 6.0-35.4), and median overall survival of 56.0 weeks (95% confidence interval: 16.3- upper limit not estimable). The toxicity profile was in the expected range. CONCLUSIONS:Afatinib did not show the expected potential for disease control in NSCLC. However, more than half of the patients in the full cohort achieved disease control at 12 weeks.
Authors: Tejas Patil; Rao Mushtaq; Sydney Marsh; Christine Azelby; Miheer Pujara; Kurtis D Davies; Dara L Aisner; William T Purcell; Erin L Schenk; Jose M Pacheco; Paul A Bunn; D Ross Camidge; Robert C Doebele Journal: Clin Lung Cancer Date: 2019-11-21 Impact factor: 4.785
Authors: Xiuning Le; Robin Cornelissen; Marina Garassino; Jeffrey M Clarke; Nishan Tchekmedyian; Jonathan W Goldman; Szu-Yun Leu; Gajanan Bhat; Francois Lebel; John V Heymach; Mark A Socinski Journal: J Clin Oncol Date: 2021-11-29 Impact factor: 44.544
Authors: Philippe L Bedard; Shuli Li; Kari B Wisinski; Eddy S Yang; Sewanti A Limaye; Edith P Mitchell; James A Zwiebel; Jeffrey A Moscow; Robert J Gray; Victoria Wang; Lisa M McShane; Larry V Rubinstein; David R Patton; P Mickey Williams; Stanley R Hamilton; Barbara A Conley; Carlos L Arteaga; Lyndsay N Harris; Peter J O'Dwyer; Alice P Chen; Keith T Flaherty Journal: JCO Precis Oncol Date: 2022-07
Authors: Bob T Li; Egbert F Smit; Yasushi Goto; Kazuhiko Nakagawa; Hibiki Udagawa; Julien Mazières; Misako Nagasaka; Lyudmila Bazhenova; Andreas N Saltos; Enriqueta Felip; Jose M Pacheco; Maurice Pérol; Luis Paz-Ares; Kapil Saxena; Ryota Shiga; Yingkai Cheng; Suddhasatta Acharyya; Patrik Vitazka; Javad Shahidi; David Planchard; Pasi A Jänne Journal: N Engl J Med Date: 2021-09-18 Impact factor: 176.079
Authors: Alessandro Russo; Ana Rita Lopes; Michael G McCusker; Sandra Gimenez Garrigues; Giuseppina R Ricciardi; Katherine E Arensmeyer; Katherine A Scilla; Ranee Mehra; Christian Rolfo Journal: Curr Oncol Rep Date: 2020-04-16 Impact factor: 5.075